Zuranolone

CHEMBL4105630 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

409.6 g/mol

LogP

4.5

Phase

4

Zuranolone is a neuroactive steroid and positive allosteric modulator of GABA-A receptors that binds to synaptic and extrasynaptic GABA-A receptor complexes, enhancing chloride ion conductance and overall inhibitory neurotransmission to reduce neuronal hyperexcitability associated with mood disorders. It is approved as a two-week oral treatment course for major depressive disorder and postpartum depression, offering rapid onset of antidepressant effects. Unlike SSRIs, it targets GABAergic rather than monoaminergic pathways, potentially addressing neurobiological underpinnings of depression related to GABA deficiency.

Moleküler Ağırlık

409,6000 g/mol

LogP

4,50

TPSA

78,90 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Bipolar Disorder Insomnia Stroke Major Depressive Disorder

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1

InChI

InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1

Molecular Formula

C25H35N3O2

HBD / HBA

1 / 4

Döndürülebilir Bağlar

3

Ağır Atomlar

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Zuranolone is a neuroactive steroid and positive allosteric modulator of GABA-A receptors that binds to synaptic and extrasynaptic GABA-A receptor complexes, enhancing chloride ion conductance and overall inhibitory neurotransmission to reduce neuronal hyperexcitability associated with mood disorders. It is approved as a two-week oral treatment course for major depressive disorder and postpartum depression, offering rapid onset of antidepressant effects. Unlike SSRIs, it targets GABAergic rather than monoaminergic pathways, potentially addressing neurobiological underpinnings of depression related to GABA deficiency.

Yes, Zuranolone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4105630. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 86294073. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Zuranolone PillFYI'da

Yapı

Hızlı Veriler

Formül: C25H35N3O2
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.